Women whose platinum-sensitive ovarian cancer has relapsed lived a little longer and had fewer side effects on a new combination of drugs compared to the standard treatment, a new study has found.

The new regimen features a combination of carboplatin and something called pegylated liposomal doxorubicin. Women on this new regimen went just under two months longer before their disease began to progress compared to women on the standard treatment of carboplatin and paclitaxel. But they had much lower rates of neutropenia, neuropathy and alopecia. They did face higher rates of thrombrocytopenia and an inflammatory condition.

You can find more details about the study here.